1Greenword RS. Adverse effects of antiepileptic drugs[J]. Epilepsia, 2000, 41(Suppl2):S42-52.
2Harden CL. Therapeutic safety monitoring:what to look for and when to look for it[J]. Epilepsia, 2000,41(Suppl 8) :S37-44.
3Withhold W. Monitoring of bone turnover biological, preanalytical and technical criteria in the assessment of biochemical markers[J]. Eur J Clin Chem Clin Biochem, 1996,34(10)785-799.
4Kanzaki S, Hosoda K, Moriwake T, et al. Serum propeptide and intact molecular osteocalcin in normal children and children with growth hormone (GH) deficiency:a potential marker of bone growth and response to GH therapy[J]. J Clin Endoerind Metab, 1992, 75(4):1104-1109.
5Tahtela R, Turperinen M, Sorva R, et al. The aminoterminal propeptide of type Ⅰ procollagen: evaluation of a commercial radioimmunoassay kit and values in healthy subjects[J]. Clin Biochem, 1997,30(1) : 35-40.
6Blumsohn A, Hannon RA, Wrate R, et al. Biochemical markers of bone turnover in girls during puberty[J]. Clin Endocrinol,1994, 40(5):663-670.
8Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy [J]. Epilepsia, 2001, 42(9) : 1141-1147.
9Alison M, Pack MD. The association between antiepileptic drugs and bone disease[J]. Epilepsy Curr, 2003,3(3) : 91-95.
10Telci A, Cakstay U, Kurt BB, et al. Changes in bone turnover and deoxypyridinoline levels in epileptic patients [J].ClinChem Lab Med, 2000, 38(1):47-50.
